Patient-reported outcomes with nivolumab plus cabozantinib in advanced kidney cancer
Ongoing results from the phase 3 CheckMate-9ER clinical trial with nivolumab plus cabozantinib have been [...]
First-line nivolumab plus ipilimumab in kidney cancer patients without nephrectomy
A recent post hoc analysis of the CheckMate 214 trial [...]
Real world incidence of immune-related side effects to ipilimumab/nivolumab in kidney cancer patients
A recent study published in Journal of Clinical Medicine this [...]
SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland
The Scottish Medicines Consortium (SMC) has approved the use of [...]
ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up
The use of two medicines together (combination therapies) for previously [...]
ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)
Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]
ASCO 2021: Gut microbiome boosts nivolumab/ipilimumab activity
Recent evidence suggests that the bacteria in the gut (the [...]
ASCO 2021: Nivolumab plus ipilimumab for the treatment of kidney cancer brain metastases
Brain metastases resulting from the spread of renal cell carcinoma [...]
ASCO 2021: Baseline characteristics affect survival with nivolumab plus cabozantinib
Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]
ASCO 2021: Nivolumab plus cabozanitinib for non-clear cell kidney cancer
The cabozantinib/nivolumab combination has been shown to be effective at [...]
